Patents by Inventor Lennart Zabeau

Lennart Zabeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1 AND PD-L1 BINDING AGENTS
    Publication number: 20230295304
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: October 5, 2022
    Publication date: September 21, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • CD8 BINDING AGENTS
    Publication number: 20230142099
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: December 1, 2022
    Publication date: May 11, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
    Publication number: 20230103946
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 6, 2023
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • CD8 binding agents
    Patent number: 11566072
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 31, 2023
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • CONJUGATED CHIMERIC PROTEINS
    Publication number: 20220378925
    Abstract: The present invention relates, in part, to pegylated chimeric proteins comprising one or more targeting moieties, linkers, and one or more signaling moieties, or variants thereof, and their use as therapeutic agents.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 1, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU
  • PD-1 and PD-L1 binding agents
    Patent number: 11498966
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 15, 2022
    Assignees: Orionis Biosciences Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • FIBROBLAST ACTIVATION PROTEIN BINDING AGENTS AND USE THEREOF
    Publication number: 20220332844
    Abstract: The present invention relates, in part, to agents, chimeric proteins and protein complexes that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents, chimeric proteins and protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 20, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU
  • Therapeutic interferon alpha 1 proteins
    Patent number: 11440943
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: September 13, 2022
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Erik Depla, Lennart Zabeau, Jan Tavernier
  • CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3)
    Publication number: 20220177550
    Abstract: Chimeric proteins or chimeric protein complexes, such as an Fc-based chimeric protein complexes directed to FMS-like tyrosine kinase 3 (FLT3), optionally composed of a FMS-like tyrosine kinase 3L (FLT3L) domain and human cytokines, which find use in, e.g., cancer treatments, are described.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • CLEC9A-BASED CHIMERIC PROTEIN COMPLEXES
    Publication number: 20220153801
    Abstract: The present invention relates, in part, to chimeric protein complexes including an anti-Clec9A targeting moiety, a modified Fc domain, and a modified human IFN? and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 19, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • MODULATION OF DENDRITIC CELL LINEAGES
    Publication number: 20220119472
    Abstract: The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 21, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Lennart ZABEAU, Erik DEPLA
  • TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF
    Publication number: 20210403525
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 30, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN, Lennart ZABEAU
  • Targeted mutant interferon-gamma and uses thereof
    Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • TARGETING OF HUMAN INTERFERON ANTAGONISTS
    Publication number: 20210238247
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: February 9, 2021
    Publication date: August 5, 2021
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • TARGETED ENGINEERED INTERFERON AND USES THEREOF
    Publication number: 20210230291
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: December 24, 2020
    Publication date: July 29, 2021
    Inventors: Nikolai KLEY, Lennart ZABEAU, Jan TAVERNIER
  • Targeting of human interferon antagonists
    Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Targeted engineered interferon and uses thereof
    Patent number: 10906985
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 2, 2021
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Lennart Zabeau, Jan Tavernier
  • CLEC9A BINDING AGENTS AND USE THEREOF
    Publication number: 20210024637
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF
    Publication number: 20210024631
    Abstract: The present invention relates, in part, to Fc-based chimeric protein complexes and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Fc-based chimeric protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • PD-1 AND PD-L1 BINDING AGENTS
    Publication number: 20200407448
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 31, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA